Dabigatran

The phase 3 OCEANIC-AF trial, comparing the novel factor XI inhibitor asundexian with apixaban in atrial fibrillation patients, was halted early due to futility, raising questions about the future of factor XI inhibitors. Despite early promise, asundexian showed inferior stroke prevention compared to apixaban, with a higher risk of ischemic stroke. Experts suggest the trial's outcome may be due to insufficient factor XI inhibition and emphasize the importance of ongoing research and clinical trials to address the unmet need in anticoagulation therapy.

The CHORMES study is a randomized, double-blind, placebo-controlled trial investigating mesoglycan for treating acute hemorrhoidal disease (HD).

A prospective observational study, XARENO, indicates that rivaroxaban reduces adverse kidney outcomes in atrial fibrillation patients with advanced chronic kidney disease (CKD).

A recent analysis of Pfizer's global safety database reveals a low reporting rate (0.005%) of drug-drug interactions (DDIs) associated with nirmatrelvir/ritonavir (NMV/r).